SCOPUS 정보 검색 플랫폼

Acta Oncologica

Volumn 47, Issue 2, 2008, Pages 323-324

Deafness associated with the use of Bortezomib in multiple myeloma [4]

(2) Chim, C S a,c Wong, L G b

a UNIVERSITY OF HONG KONG (Hong Kong)

b TUEN MUN HOSPITAL (Hong Kong)

c QUEEN MARY HOSPITAL (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MELPHALAN; PREDNISOLONE; THALIDOMIDE; VINCRISTINE;

ADULT; CANCER CHEMOTHERAPY; CASE REPORT; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HEARING IMPAIRMENT; HERPES ZOSTER; HUMAN; LETTER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OTOTOXICITY; PERCEPTION DEAFNESS; PRIORITY JOURNAL; PRURITUS; PURE TONE AUDIOMETRY; RASH; REMISSION; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FATAL OUTCOME; FEMALE; HEARING LOSS, SENSORINEURAL; HUMANS; IMMUNOGLOBULIN A; MULTIPLE MYELOMA; PYRAZINES; RISK FACTORS;

EID: 38349141864 PISSN: 0284186X EISSN: 1651226X Source Type: Journal
DOI: 10.1080/02841860701558823 Document Type: Letter

Times cited : (7)

References (6)

1
- 0037973279
- A phase 2 study of bortezomib in relapsed, refractory myeloma
- Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
- (2003) N Engl J Med , vol.348 , pp. 2609-2617
- Richardson, P.G.¹ Barlogie, B.² Berenson, J.³ Singhal, S.⁴ Jagannath, S.⁵ Irwin, D.⁶

2
- 20444433230
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
- Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
- (2005) N Engl J Med , vol.352 , pp. 2487-2498
- Richardson, P.G.¹ Sonneveld, P.² Schuster, M.W.³ Irwin, D.⁴ Stadtmauer, E.A.⁵ Facon, T.⁶

3
- 33748287079
- Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study
- Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood 2006;108:2165-72.
- (2006) Blood , vol.108 , pp. 2165-2172
- Mateos, M.V.¹ Hernandez, J.M.² Hernandez, M.T.³ Gutierrez, N.C.⁴ Palomera, L.⁵ Fuertes, M.⁶

4
- 0020073571
- The pharmacology of ototoxic drugs
- Harpur ES. The pharmacology of ototoxic drugs. Br J Audiol 1982;16:81-93.
- (1982) Br J Audiol , vol.16 , pp. 81-93
- Harpur, E.S.¹

5
- 18644372165
- Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient
- Engelhardt M, Muller AM, Maier W, Wasch R. Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient. Leukemia 2005;19:869-70.
- (2005) Leukemia , vol.19 , pp. 869-870
- Engelhardt, M.¹ Muller, A.M.² Maier, W.³ Wasch, R.⁴

6
- 33746010219
- Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
- Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-20.
- (2006) J Clin Oncol , vol.24 , pp. 3113-3120
- Richardson, P.G.¹ Briemberg, H.² Jagannath, S.³ Wen, P.Y.⁴ Barlogie, B.⁵ Berenson, J.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.